Castle Biosciences Inc: Business Overview, Financials & Competitive Analysis
Castle Biosciences Inc scores 8/10 on the AskCyborg Cyborg Score (Strong). High-growth molecular diagnostics company with expanding test portfolio, strong clinical validation, and demonstrated ability to drive volume growth in attractive oncology and gastroenterology markets. Castle demonstrates strong fundamentals with 37% growth in core test volumes (2025), significant revenue expansion to $344M, and robust analyst conviction. The company operates in.
What is Castle Biosciences Inc's industry? Castle Biosciences Inc (castlebiosciences.com) operates in In-Vitro Diagnostics. AskCyborg classifies Castle Biosciences Inc under In-Vitro Diagnostics in its company registry.
Castle Biosciences is a molecular diagnostics company that provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company lever...
Cyborg Score thesis
High-growth molecular diagnostics company with expanding test portfolio, strong clinical validation, and demonstrated ability to...
Read the full analyst-debate transcript →Get the Latest Castle Biosciences Inc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCastle Biosciences Inc Overview
Pro stress-test →Castle Biosciences is a molecular diagnostics company that provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company leverages gene expression profiling and spatialomics technologies to deliver personalized, clinically actionable molecular tests that guide treatment decisions for patients and clinicians.
Strategic Profile
Pro stress-test →In 2025, Castle achieved total test reports for core revenue drivers (DecisionDx-Melanoma and TissueCypher) increasing 37% over 2024, and exceeded full-year revenue guidance at $344 million. The company maintains strong analyst sentiment with an average "Strong Buy" rating and a 12-month stock price target of $47.17, representing an 84.55% upside from current levels.
Competitive Landscape
Pro stress-test →Castle competes in the precision oncology diagnostics and molecular testing space against companies like Guardant Health (liquid biopsies for cancer), Myriad Genetics (genetic testing and oncology diagnostics), and Exact Sciences (cancer screening and diagnostics). Castle's differentiation lies in its focus on solid tumor risk stratification, spatialomics technology (TissueCypher), and expansion into adjacent high-value clinical areas like Barrett's esophagus management.
Industry Context
Castle Biosciences Inc operates in In-Vitro Diagnostics.
Key facts
Founded: 2007 · Headquarters: Friendswood, Texas, US · Employees: 761 · Revenue: $344M (2025) · Market cap: $879.2M